mTOR抑制剂在乳腺癌内分泌及HER-2靶向治疗耐药中的研究进展  

Progress of research on mTOR inhibitor in endocrine and HER-2 targeted therapy resistance in breast cancer

作　　者：段海明[1] 郑艳妮 王闽全[1] 

机构地区：[1]新疆医科大学第二附属医院肿瘤外科,乌鲁木齐830063 [2]陕西摩美得制药有限公司

出　　处：《国际肿瘤学杂志》2015年第5期377-380,共4页Journal of International Oncology

摘　　要：哺乳动物雷帕霉素靶蛋白（mTOR）位于磷脂酰肌醇3激酶（PI3K）-蛋白激酶 B（Akt）细胞信号通路的下游，已有研究表明该通路的异常激活与乳腺癌的内分泌及抗人表皮生长因子受体-2（HER-2）的靶向治疗耐药相关。在既往传统药物的基础上通过联合 mTOR 抑制剂阻断该条通路的异常活化，在防止肿瘤细胞的耐药性发展及恢复初始敏感性方面均体现出了良好的应用前景，mTOR 抑制剂将有望成为乳腺癌治疗的新希望。Mammalian target of rapamycin（mTOR）locates at the downstream of phosphatidylinositol 3 kinase（PI3K）-protein kinase B（Akt）cell signal transduction pathway. Studies find that the abnormal activa-tion of this pathway is correlated with the endocrine and drug resistance of anti human epidermal growth factor receptor-2（HER-2）target therapy in breast cancer. The combination with mTOR inhibitors based on the past traditional drugs can block the pathway and reflect a favourable application prospect in preventing the develop-ment of resistance and restoring the initial sensitivity on tumor cells. mTOR inhibitors are expected to be the new hope for the treatment of breast cancer.

关 键 词：乳腺肿瘤 西罗莫司 MTOR抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]